Effects of multiple doses of voriconazole on the vision of healthy volunteers: A double-blind, placebo-controlled study

Ophthalmic Research

Volumn 52, Issue 1, 2014, Pages 43-52

  Zrenner, Eberhart ^a   Tomaszewski, Konrad ^b   Hamlin, Julia ^b   Layton, Gary ^b   Wood, Nolan ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Antifungal; Blurred vision; Electroretinogram; Enhanced visual perceptions; Photophobia; Retina; Vision; Voriconazole

Indexed keywords

PLACEBO; VORICONAZOLE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; ANTIFUNGAL AGENT;

A WAVE; ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; B WAVE; BLURRED VISION; COLOR VISION DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; ELECTRORETINOGRAM; FOLLOW UP; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MIDDLE AGED; NORMAL HUMAN; OSCILLATORY POTENTIAL; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISION; VISION TEST; VISUAL FIELD; VISUAL SYSTEM EXAMINATION; YOUNG ADULT; ABNORMAL VISION; CLINICAL ARTICLE; COLOR VISION; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; EYE PAIN; GENOTYPE; PERIMETRY; SIDE EFFECT; SIGNAL NOISE RATIO; TREATMENT DURATION; VISUAL ACUITY; DRUG EFFECTS; ELECTRORETINOGRAPHY; ORAL DRUG ADMINISTRATION; PHOTORECEPTOR CELL;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; COLOR VISION; DOUBLE-BLIND METHOD; ELECTRORETINOGRAPHY; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PHOTORECEPTOR CELLS, VERTEBRATE; VISUAL FIELDS; VISUAL PERCEPTION; VORICONAZOLE; YOUNG ADULT;

EID: 84902016335     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000359952     Document Type: Article

References (18)

1. Boucher HW, Groll AH, Chiou CC, Walsh TJ: Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-2020.
2. Florea NR, Kuti JL, Quintiliani R: Voriconazole. A novel azole antifungal. Formulary 2002; 37: 389-399.
3. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, De Pauw B: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
4. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
5. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-1442.
6. Birch DG: Surrogate electroretinographic markers for assessing therapeutic efficacy in the retina. Expert Rev Mol Diagn 2004; 4: 693-703.
7. Zrenner E: The role of electrophysiology and psychophysics in ocular toxicology; in Fraunfelder FT, Fraunfelder WA, Chambers WA (eds): Clinical Ocular Toxicology. Philadelphia, Elsevier, 2008, pp 21-38.
8. Pfizer Inc: FDA Antiviral Drugs Advisory Committee: briefing document for voriconazole (oral and intravenous formulations). 2001. www.fda.gov/ohrms/ dockets/ac/01/brie fing/3792b2-01-pfizer.pdf (accessed October 4, 2013).
9. Marmor MF, Zrenner E: Standard for clinical electroretinography (1999 update). International Society for Clinical Electrophysiology of Vision. Doc Ophthalmol 1999; 97: 143-156.
10. Mantyjarvi M: Normal test scores in the Farnsworth-Munsell 100 hue test. Doc Ophthalmol 2001; 102: 73-80.
11. Park HJ, Kim DM, Youn DH, Hong C: Detection of early visual field change in ocular hypertension using STATPAC. Korean J Ophthalmol 1990; 4: 16-22.
12. Hardy KJ, Craven B, Foster DH, Scarpello JH: Extent and duration of practice effects on performance with the Farnsworth-Munsell 100-hue test. Ophthalmic Physiol Opt 1994; 14: 306-309.
13. Gouras P, MacKay CJ: Light adaptation of the electroretinogram. Diminished in retinitis pigmentosa. Invest Ophthalmol Vis Sci 1989; 30: 619-624.
14. Sterling P, Matthews G: Structure and function of ribbon synapses. Trends Neurosci 2005; 28: 20-29.
15. Banin E, Shalev RS, Obolensky A, Neis R, Chowers I, Gross-Tsur V: Retinal function abnormalities in patients treated with vigabatrin. Arch Ophthalmol 2003; 121: 811-816.
16. Krauss GL, Johnson MA, Miller NR: Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614-618.
17. Zrenner E, Apfelstedt-Sylla E, Rüther K: Clinical aspects: retinitis pigmentosa; in Djamgoz MBA, Archer SN, Vallerga S (eds): Neurobiology and Clinical Aspects of the Outer Retina. London, Chapman & Hall, 1995, pp 447-460.
18. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N: Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46: 235-243.